Abstract
Emission tomography techniques and, in particular, positron emission tomography (PET) enable the in vivo study of several physiological and neurochemical variables in human subjects using methods originally developed for quantitative autoradiography. In particular, PET allows one to evaluate in human subjects: (a) the effect of specific neurochemical challenges on regional brain function at rest or under activation; (b) the activity of neurotransmitters and the regional expression of specific molecular targets during pathology including their modulation by drug treatment; (c) the kinetics of drug disposition and activity directly in the target organ. This is of primary interest in the field of biological psychiatry and in psychoactive drugs development, where it is particularly difficult to reproduce human diseases using animal models in view of the peculiarity of this field and the large heterogeneity of each psychiatric illness also inside the same clinical definition. The aim of this paper is to review the principal strategies and the main results of the use of PET or single photon emission tomography (SPET) molecular imaging for the in vivo study of serotonin receptors and the main results obtained from their application in the study of major depression.
Keywords: SEROTONIN RADIOLIGAND, psychiatric disorders, SERT binding sites, Fluvoxamine, paroxetine, depression
Current Topics in Medicinal Chemistry
Title: PET and SPET Molecular Imaging: Focus on Serotonin System
Volume: 6 Issue: 18
Author(s): Rosa Maria Moresco, Mario Matarrese and Ferruccio Fazio
Affiliation:
Keywords: SEROTONIN RADIOLIGAND, psychiatric disorders, SERT binding sites, Fluvoxamine, paroxetine, depression
Abstract: Emission tomography techniques and, in particular, positron emission tomography (PET) enable the in vivo study of several physiological and neurochemical variables in human subjects using methods originally developed for quantitative autoradiography. In particular, PET allows one to evaluate in human subjects: (a) the effect of specific neurochemical challenges on regional brain function at rest or under activation; (b) the activity of neurotransmitters and the regional expression of specific molecular targets during pathology including their modulation by drug treatment; (c) the kinetics of drug disposition and activity directly in the target organ. This is of primary interest in the field of biological psychiatry and in psychoactive drugs development, where it is particularly difficult to reproduce human diseases using animal models in view of the peculiarity of this field and the large heterogeneity of each psychiatric illness also inside the same clinical definition. The aim of this paper is to review the principal strategies and the main results of the use of PET or single photon emission tomography (SPET) molecular imaging for the in vivo study of serotonin receptors and the main results obtained from their application in the study of major depression.
Export Options
About this article
Cite this article as:
Moresco Rosa Maria, Matarrese Mario and Fazio Ferruccio, PET and SPET Molecular Imaging: Focus on Serotonin System, Current Topics in Medicinal Chemistry 2006; 6 (18) . https://dx.doi.org/10.2174/156802606778522140
DOI https://dx.doi.org/10.2174/156802606778522140 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design MMP-9, a Potential Target for Cerebral Ischemic Treatment
Current Neuropharmacology Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
Current Neuropharmacology Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design The Plasticity of the 7TMR Signaling Machinery and the Search for Pharmacological Selectivity
Current Pharmaceutical Design Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of Schizophrenia. Current Evidence and Future Directions
Current Pharmaceutical Design Endogenous Opioids and Addiction to Alcohol and other Drugs of Abuse
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Current Neuropharmacology Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry Elucidating Treatment of Alzheimer's Disease via Different Receptors
Current Topics in Medicinal Chemistry A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?
Current Alzheimer Research Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
Current Pharmaceutical Design Synaptic Dysfunction in Synucleinopathies
CNS & Neurological Disorders - Drug Targets Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Aminergic Control and Modulation of Honeybee Behaviour
Current Neuropharmacology β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry